Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma

References

• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2012. Available from: www.ginasthma.com/Guidelines/guidelines-resources.html [last accessed 22 Dec 2014]
   Google Scholar
• National Institutes of Health. Guidelines for the diagnosis and management of asthma (EPR-3) 2007. NHLBI, August 2007. NIH publication no. 08-4051. Available from: www.nhlbi.nih.gov/guidelines/asthma/index.htm [last accessed 22 Dec 2014]
   Google Scholar
• British Thoracic Society (BTS). British Guideline on the Management of Asthma. London, UK. Available from: www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthma-guideline [last accessed 22 Dec 2014]
   Google Scholar
• Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481–1488
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405–1411
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010;5:CD005535
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Busse WW, Lötvall J, Snowise NG, Frith L, Jacques L, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res 2011;12:160. doi: 10.1186/1465-9921-12-160
   PubMed Web of Science ®Google Scholar
• Sterling R, Lim J, Frith L, Snowise NG, Jacques L, Haumann B. Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med 2012;106:1110–1115
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bleecker ER, Lötvall J, Woodcock A, Forth R, Medley H, Davis AM, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med 2012;106:642–650
   PubMed Web of Science ®Google Scholar
• Busse W, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, et al. Fluticasone furoate demonstrates efficacy in asthma patients symptomatic on medium doses of inhaled corticosteroid therapy: a randomised, placebo-controlled trial. Thorax 2012;67:35–41
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Bateman ED, Busse WW, Woodcock A, Frith L, House KW, Jacques L, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol 2012;109:353–358
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Lötvall J, O’Byrne PM, Woodcock A, Busse WW, Kerwin EM, Forth R, et al. Fluticasone furoate–vilanterol 100–25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol In Pract 2014;2:553–561
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bateman ED, Bleecker ER, Busse WW, Woodcock A, Follows R, Lim J, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with ICSs. Eur Respir J 2012;40:570–579
   PubMed Web of Science ®Google Scholar
• Emilsson M, Berndtsson I, Lötvall J, Millqvist E, Lundgren J, Johansson A, Brink E. The influence of personality traits and beliefs about medicines on adherence to asthma treatment. Prim Care Respir J 2011;20:141–147
   PubMedGoogle Scholar
• Navaratnam P, Friedman HS, Urdaneta E. Treatment with inhaled mometasone furoate reduces short-acting β(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients. Value Health 2011;14:339–346
   PubMed Web of Science ®Google Scholar
• Friedman HS, Navaratnam P, McLaughlin J. Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma. J Asthma 2010;47:994–1000
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manage Care 2009;15:e22–e33
   PubMed Web of Science ®Google Scholar
• Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010;10:1
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, Nunn C, O’Byrne PM. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma. Am J Respir Crit Care Med 2014;189:A6671
   Google Scholar
• World Medical Association. Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Available from: www.wma.net/en/30publications/10policies/b3/17c.pdf [last accessed 22 Dec 2014]
   Google Scholar
• International Conference on Harmonisation Tripartite Guideline: Guidance for Good Clinical Practice E6 (R1). Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf [last accessed 22 Dec 2014]
   Google Scholar
• O’Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J 2014;43:773–782
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81–87
   PubMed Web of Science ®Google Scholar
• Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19:398–404
   PubMed Web of Science ®Google Scholar
• Bateman ED, O’Byrne PM, Busse WW, Lötvall J, Bleecker ER, Andersen L, Jacques L, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax 2014;69:312–319
   PubMed Web of Science ®Google Scholar
• Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev 2009;7:CD005307
   Google Scholar
• Clark M, Martin S, Svedsater H, Dale P, Jacques L. Measurement properties of an asthma symptom and rescue medication use diary. J Asthma 2015;52:88–97
   PubMed Web of Science ®Google Scholar
• Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009;124:719–723
   PubMed Web of Science ®Google Scholar
• Woodcock A, Lötvall J, Busse WW, Bateman ED, Stone S, Ellsworth A, Jacques L. Efficacy and safety of fluticasone furoate 100 µg and 200 µg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. BMC Pulm Med 2014;14:113
   PubMed Web of Science ®Google Scholar
• Busse WW, O’Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, Hicks W, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial. Thorax 2013;68:513–520
   PubMed Web of Science ®Google Scholar
• Mattishent K, Thavarajah M, Blanco P, Gilbert D, Wilson AM, Loke YK. Meta-review: adverse effects of inhaled corticosteroids relevant to older patients. Drugs 2014;74:539–547
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466–476
   PubMed Web of Science ®Google Scholar
• Eisner MD, Klein J, Hammond SK, Koren G, Lactao G, Iribarren C. Directly measured second hand smoke exposure and asthma health outcomes. Thorax 2005;60:814–821
   PubMed Web of Science ®Google Scholar